| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
BCI-137 targets Argonaute 2 (AGO2), specifically binding tightly to multiple residues in the Mid domain of the protein. It acts as a competitive antagonist, inhibiting AGO2 function in the RNA-induced silencing complex.
|
|---|---|
| ln Vitro |
In cell-free biochemical assays, BCI-137 inhibits AGO2 activity with an IC₅₀ of 342 μM. The compound binds to the Mid domain of AGO2, disrupting its function in the RNA-induced silencing complex. Detailed mechanistic studies would be required to fully characterize its inhibition kinetics.
|
| ln Vivo |
Cells treated with BCI-137 would show inhibition of AGO2-mediated gene silencing. The compound is used to study the role of AGO2 and the RNAi pathway in various cellular processes including gene regulation, development, and disease. Cellular effects would depend on the specific microRNA and target gene contexts.
|
| Enzyme Assay |
The in vitro AGO2 inhibition assay involves incubating recombinant AGO2 protein or immunoprecipitated AGO2 complexes with varying concentrations of BCI-137. Enzyme activity is measured by assessing the cleavage of target RNA or the binding of microRNA guides. IC₅₀ values are calculated from dose-response curves. Binding to the Mid domain can be assessed by surface plasmon resonance or similar techniques.
|
| Cell Assay |
Cells are cultured and treated with BCI-137 at concentrations ranging from 1 µM to 1 mM. AGO2-mediated gene silencing is assessed by measuring the expression of known microRNA target genes using qRT-PCR or reporter assays. Cell viability is monitored to assess compound toxicity.
|
| Animal Protocol |
In vivo studies for BCI-137 would be conducted in appropriate animal models to evaluate the effects of AGO2 inhibition. The compound would be administered via routes such as intraperitoneal injection or oral gavage. Endpoints would include assessment of gene expression changes and phenotypic effects related to RNAi pathway disruption.
|
| ADME/Pharmacokinetics |
BCI-137 (C₁₁H₁₁N₃O₆S, MW 313.29, CAS 112170-24-8) is a small molecule compound. It is soluble in DMSO. The compound is typically stored as a powder at -20°C for up to 3 years. In vivo formulations include DMSO:Tween 80:Saline = 10:5:85.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology data for BCI-137 are limited. The compound is for research use only and is not approved for clinical use. Standard safety precautions should be followed when handling the compound.
|
| Additional Infomation |
BCI-137 (also known as BCI 137 and BCI137) is a research tool for studying AGO2 function and the RNA interference pathway. It is used in studies of gene regulation and the role of AGO2 in various biological processes. The compound is intended for laboratory use only.
|
| Molecular Formula |
C11H11N3O6S
|
|---|---|
| Molecular Weight |
313.287
|
| Exact Mass |
313.036
|
| CAS # |
112170-24-8
|
| PubChem CID |
3157172
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.612
|
| LogP |
-1.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
569
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(NS(=O)(=O)C1=CC=C2NC(=O)C(=O)NC2=C1)C(O)=O
|
| InChi Key |
VMSRTLYZOWBBFW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H11N3O6S/c1-5(11(17)18)14-21(19,20)6-2-3-7-8(4-6)13-10(16)9(15)12-7/h2-5,14H,1H3,(H,12,15)(H,13,16)(H,17,18)
|
| Chemical Name |
2-(2,3-Dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonamido) propanoic acid
|
| Synonyms |
BCI-137 BCI 137 BCI137
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1919 mL | 15.9597 mL | 31.9193 mL | |
| 5 mM | 0.6384 mL | 3.1919 mL | 6.3839 mL | |
| 10 mM | 0.3192 mL | 1.5960 mL | 3.1919 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA